See more : HYBE Co., Ltd. (352820.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Mydecine Innovations Group Inc. (MYCOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Viji Finance Limited (VFL.BO) Income Statement Analysis – Financial Results
- Ensign Energy Services Inc. (ESI.TO) Income Statement Analysis – Financial Results
- Landcadia Holdings III, Inc (LCYAU) Income Statement Analysis – Financial Results
- MEP Infrastructure Developers Limited (MEP.NS) Income Statement Analysis – Financial Results
- GRM Overseas Limited (GRMOVER.BO) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K | 0.00 |
| Cost of Revenue | 9.88K | 128.86K | 0.00 | 37.37K | 94.05K | 109.82K | 246.58K | 1.77M | 1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.88K | -128.86K | 7.49K | 21.12K | 31.52K | 97.83K | -246.58K | -1.77M | -1.88M | 84.00K | 49.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | -2,243.43% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.08M | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.15M | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K | 0.00 |
| Selling & Marketing | 1.15M | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 | 0.00 |
| SG&A | 8.30M | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K | 12.97 |
| Other Expenses | 0.00 | 2.82M | 3.99M | 292.02K | 149.99K | -4.54M | -97.92K | -4.28K | -2.95K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.64M | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Cost & Expenses | 19.64M | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Interest Income | 0.00 | 911.59 | 205.27 | 24.67 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 | 44.97 |
| Interest Expense | 1.30M | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K | 0.00 |
| Depreciation & Amortization | 9.88K | 128.86K | 235.18K | 57.08K | 46.39K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K | 26.58 |
| EBITDA | -9.38M | -15.92M | -23.14M | -11.12M | -3.21M | -5.78M | -15.46M | -4.18M | -3.83M | -1.17M | 1.44K | -14.21 |
| EBITDA Ratio | 0.00% | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% | 0.00% |
| Operating Income | -9.39M | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K | -40.80 |
| Operating Income Ratio | 0.00% | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% | 0.00% |
| Total Other Income/Expenses | -11.55M | -1.40M | -515.87K | -15.67M | -18.04M | -7.55M | -1.99M | -3.79M | -264.53K | -464.40K | -83.34K | -45.24 |
| Income Before Tax | -20.95M | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K | -86.03 |
| Income Before Tax Ratio | 0.00% | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| Income Tax Expense | 0.00 | -5.39M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K | 0.00 |
| Net Income | -20.95M | -11.85M | -28.72M | -27.56M | -3.73M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K | -86.03 |
| Net Income Ratio | 0.00% | 0.00% | -383,287.92% | -47,114.19% | -2,968.22% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| EPS | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.45 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| EPS Diluted | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| Weighted Avg Shares Out | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.37K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
| Weighted Avg Shares Out (Dil) | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
Mydecine's Prospects Look Magical, Like A Mushroom
Mydecine to launch Phase 2A clinical trial on psilocybin assisted psychotherapy to treat PTSD in veterans
Mydecine selects substance use disorder and smoking cessation for its psychedelic molecule MYCO-004
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th
Roth says Mydecine Innovations has blockbuster potential with its MYCO-001 psychedelic therapy as it initiates coverage
Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Source: https://incomestatements.info
Category: Stock Reports